article thumbnail

STAT+: Documents detail how pharmacy giants Walgreens, CVS, and Walmart failed patients in the opioid epidemic

STAT

In 2011, Walgreens executives were under pressure. Amid a growing addiction crisis, and with the country already awash in prescription painkillers, the federal government was demanding accountability from the pharmacy giant for filling thousands of opioid prescriptions written by doctors in suspiciously large quantities.  

article thumbnail

STAT+: Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more

STAT

regulators in 2011. The FDA still has to make a decision on whether to officially place semaglutide on the lists. Novo has repeatedly argued that compounded products are risky, stressing that they are not approved by the FDA. Eylea can treat eye diseases like macular degeneration, macular edema, and retinopathy, and was first approved by U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

SAEM Clinical Images Series: Fever with Rash

ALiEM - Pharm Pearls

Fever was documented to be 102°F and was not associated with any chills or rigors. 2011 Oct 18;183(15):E1152. Epub 2011 Sep 12. A 40-year-old male, tailor by occupation, was brought to the Emergency Department with complaints of high-grade fever for the past 11 days. Curr Infect Dis Rep. 2009 Jan;11(1):66-72. PMID: 19094827.

article thumbnail

Increasing patient engagement with UK clinical trials

pharmaphorum

Having worked for CROs since graduating, Sophie joined Pfizer in 2011 and has had various roles within the UK and now global groups. She holds a Bachelor’s degree in Biological Sciences and a PhD in Molecular Biochemistry from the University of Reading, UK. He has participated in four interventional studies and nine others.

article thumbnail

Optimizing Your Drug Patent Strategy: A Comprehensive Guide for Pharmaceutical Companies

Drug Patent Watch

The First-to-File System Since the America Invents Act of 2011, the U.S. Clinical Development Success Rates and Contributing Factors 2011-2020. Filing too early might mean your patent expires before you’ve had a chance to fully commercialize your drug. File too late, and you risk someone else beating you to the punch.

article thumbnail

510(k) Modernization 2023

FDA Law Blog: Biosimilars

Lenz, Principal Medical Device Regulation Expert — On September 6, 2023, FDA announced its latest efforts to modernize the 510(k) process, outlining FDA’s latest improvements to strengthen the 510(k) Program and announcing release of three draft guidance documents.

article thumbnail

FDA looks at pulling speedy approvals for three cancer drugs

pharmaphorum

Briefing documents published by the FDA ahead of the meeting suggest that discussion will focus on ongoing trials that may serve as alternative confirmatory studies. A similar trial called Impassion131 of Tecentriq with regular paclitaxel flopped, and even suggested patients treated with paclitaxel alone may have fared better.